Notizia - Recent Pharma, Healthcare and Biotech Happenings
Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Feb 09, 2017
Table of Contents
AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI’s Integrated Drug Discovery Center and, in accordance with the terms of the alliance, Bruker Daltonics and HighRes Biosolutions will provide training and consulting to AMRI biologists to aid them in their development of protocols on the system that can be used for high throughput screening drug discovery programs.
Ferring Pharmaceuticals and Enteris BioPharma have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring. Enteris will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product, and will receive milestones and royalties based on net sales of the developed product.
Article in PDF
Quotient Clinical has acquired SeaView Research with the aim of expanding its operations into the U.S. The acquisition combines Quotient and SeaView’s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver a broader set of services. Each of the facilities is capable of undertaking complex clinical research studies including first-in-human investigations.
Renova Therapeutics, gene therapy specialist, has signed an agreement to receive the investigational new drug (IND) file for stresscopin from Janssen Pharmaceuticals. Stresscopin is a hormone involved in responses to physiological stress and was previously under development at Janssen. Stresscopin has been shown in preclinical studies to protect cells exposed to fluctuating oxygen levels, such as occur in the heart in cardiovascular disease. Janssen’s scientists had previously shown that stresscopin and other related peptides can increase the ability of heart cells to contract. Renova will advance the programme development as RT-400, a peptide infusion treatment for episodes of acute decompensated heart failure (ADHF), which accounts for about half of all heart failure-related causes of hospitalization in the US.
Article in PDF
